LON:STX - Shield Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
GBX 55.49
▲ +0.485 (0.88%)

This chart shows the closing price for STX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Shield Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STX

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Shield Therapeutics in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 55.49.

This chart shows the closing price for STX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Shield Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/18/2021Peel HuntReiterated RatingBuy
5/18/2021Peel HuntReiterated RatingBuy
7/16/2020Peel HuntReiterated RatingBuy
7/2/2020Peel HuntReiterated RatingBuy
6/3/2020Peel HuntReiterated RatingBuy
5/21/2020Peel HuntReiterated RatingBuy
5/21/2020FinnCapReiterated RatingCorporate
5/1/2020Peel HuntReiterated RatingBuy
5/1/2020FinnCapReiterated RatingCorporate
4/22/2020Peel HuntReiterated RatingBuy
4/22/2020FinnCapReiterated RatingCorporate
4/7/2020Peel HuntReiterated RatingBuy
3/17/2020Peel HuntReiterated RatingBuy
3/5/2020Peel HuntReiterated RatingBuy
2/5/2020Peel HuntReiterated RatingBuy
1/27/2020Peel HuntReiterated RatingBuy
1/27/2020FinnCapReiterated RatingCorporate
1/8/2020Peel HuntReiterated RatingBuyGBX 200
1/8/2020Peel HuntReiterated RatingBuyGBX 200
12/5/2019Peel HuntReiterated RatingBuy
11/4/2019Peel HuntReiterated RatingBuy
10/23/2019FinnCapReiterated RatingCorporate
10/22/2019Peel HuntReiterated RatingBuy
10/2/2019Peel HuntReiterated RatingBuyGBX 200
10/2/2019Peel HuntReiterated RatingBuyGBX 200
9/2/2019Peel HuntReiterated RatingBuy
8/7/2019Peel HuntReiterated RatingBuy
8/7/2019FinnCapReiterated RatingCorporate
8/1/2019Peel HuntReiterated RatingBuy
7/26/2019FinnCapReiterated RatingCorporate
7/22/2019Peel HuntReiterated RatingBuyGBX 88 ➝ GBX 200
7/15/2019Peel HuntReiterated RatingBuy
7/3/2019Peel HuntReiterated RatingBuy
6/3/2019FinnCapReiterated RatingCorporate
6/3/2019Peel HuntReiterated RatingBuy
5/14/2019FinnCapInitiated CoverageCorporateGBX 200
5/2/2019Peel HuntReiterated RatingBuy
4/24/2019Peel HuntReiterated RatingBuy
4/3/2019Liberum CapitalReiterated RatingBuy
4/2/2019Peel HuntReiterated RatingBuy
3/15/2019Liberum CapitalReiterated RatingBuy
3/12/2019Peel HuntBoost Price TargetBuyGBX 70 ➝ GBX 88
3/4/2019Peel HuntReiterated RatingBuy
3/4/2019Liberum CapitalReiterated RatingBuy
2/19/2019Liberum CapitalBoost Price TargetBuyGBX 80 ➝ GBX 116
1/29/2019Liberum CapitalReiterated RatingBuy
1/29/2019Peel HuntReiterated RatingBuy
1/22/2019Liberum CapitalReiterated RatingBuy
1/22/2019Peel HuntReiterated RatingBuy
1/7/2019Peel HuntReiterated RatingBuy
12/13/2018Peel HuntReiterated RatingBuy
12/4/2018Liberum CapitalReiterated RatingBuy
12/4/2018Peel HuntReiterated RatingBuy
11/1/2018Peel HuntReiterated RatingBuy
10/2/2018Peel HuntReiterated RatingBuy
10/2/2018Liberum CapitalReiterated RatingBuy
9/24/2018Peel HuntReiterated RatingBuyGBX 70
9/19/2018Liberum CapitalReiterated RatingUnder Review
9/4/2018Peel HuntReiterated RatingUnder Review
8/1/2018Peel HuntReiterated RatingUnder Review
7/23/2018Liberum CapitalReiterated RatingUnder Review
7/23/2018Peel HuntReiterated RatingUnder Review
6/28/2018Peel HuntReiterated RatingUnder Review
6/14/2018Peel HuntReiterated RatingUnder Review
5/31/2018Peel HuntReiterated RatingUnder Review
4/6/2018Peel HuntReiterated RatingUnder Review
4/6/2018Liberum CapitalReiterated RatingUnder Review
3/27/2018Peel HuntReiterated RatingUnder Review
3/16/2018Peel HuntReiterated RatingUnder Review
3/16/2018Liberum CapitalReiterated RatingUnder Review
2/22/2018Liberum CapitalReiterated RatingUnder Review
2/22/2018Peel HuntReiterated RatingUnder Review
2/5/2018Liberum CapitalReiterated RatingUnder Review
2/1/2018Peel HuntReiterated RatingBuyGBX 220
11/21/2017FinnCapReiterated RatingBuyGBX 265
11/8/2017Peel HuntReiterated RatingBuyGBX 220
10/31/2017Peel HuntReiterated RatingBuyGBX 220
10/10/2017Liberum CapitalReiterated RatingBuyGBX 245
9/22/2017FinnCapLower Price TargetBuyGBX 270 ➝ GBX 265
9/20/2017Peel HuntReiterated RatingBuyGBX 220
9/20/2017Liberum CapitalReiterated RatingBuyGBX 245
9/14/2017FinnCapReiterated RatingBuyGBX 270
9/14/2017Liberum CapitalReiterated RatingBuyGBX 245
9/7/2017FinnCapInitiated CoverageBuyGBX 270
9/6/2017Liberum CapitalReiterated RatingBuyGBX 245
7/6/2017Peel HuntReiterated RatingBuyGBX 220
6/22/2017Liberum CapitalReiterated RatingBuyGBX 245
4/25/2017Liberum CapitalReiterated RatingBuyGBX 245
4/4/2017Liberum CapitalLower Price TargetBuyGBX 310 ➝ GBX 245
3/13/2017Liberum CapitalReiterated RatingBuyGBX 310
1/6/2017Canaccord GenuityReiterated RatingBuyGBX 241
1/6/2017Liberum CapitalReiterated RatingBuyGBX 310
9/20/2016Canaccord GenuityBoost Price TargetBuyGBX 235 ➝ GBX 241
9/20/2016Liberum CapitalReiterated RatingBuyGBX 310
8/11/2016Canaccord GenuityReiterated RatingBuyGBX 235
7/18/2016Canaccord GenuityInitiated CoverageBuyGBX 235
(Data available from 6/24/2016 forward)
Shield Therapeutics logo
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of late-stage pharmaceuticals to treat unmet medical needs. The company's lead product is Ferric Maltol, marketed in the European Union as Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anaemia in adults. It also develops PT20, a novel therapy that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease; PT30 to treat hypo-allergenic IV iron therapy; and PT40, the first generic version of iron sucrose. The company was founded in 2008 and is based in Gateshead, the United Kingdom.
Read More

Today's Range

Now: GBX 55.49
Low: 54.43
High: 61

50 Day Range

MA: GBX 52.70
Low: 43
High: 60

52 Week Range

Now: GBX 55.49
Low: 31
High: 153

Volume

2,442,735 shs

Average Volume

1,603,514 shs

Market Capitalization

£119.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Shield Therapeutics?

The following sell-side analysts have issued reports on Shield Therapeutics in the last twelve months: Peel Hunt, and Peel Hunt LLP.
View the latest analyst ratings for STX.

What is the current price target for Shield Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Shield Therapeutics in the last year. has the lowest price target set, forecasting a price of £100,000 for Shield Therapeutics in the next year.
View the latest price targets for STX.

What is the current consensus analyst rating for Shield Therapeutics?

Shield Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe STX will outperform the market and that investors should add to their positions of Shield Therapeutics.
View the latest ratings for STX.

What other companies compete with Shield Therapeutics?

How do I contact Shield Therapeutics' investor relations team?

Shield Therapeutics' physical mailing address is 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom. The company's listed phone number is +44-191-5118500. The official website for Shield Therapeutics is www.shieldtherapeutics.com.